Conflicting evidence has suggested that low mean nocturnal hemoglobin oxygen saturation (SpO 2 ) predicts future hospital days for acute severe pain in children with sickle cell anemia (SCA). In an unselected multicenter prospective cohort study, we tested the hypothesis that either low mean nocturnal SpO 2 or high obstructive apnea-hypopnea index (OAHI; the number of obstructive apneas and hypopneas with 3% desaturation or arousal per hour of sleep) or high oxygen desaturation index (ODI; number of 3% desaturation from baseline saturation per hour of sleep) is associated with increased incidence rates of pain. A total of 140 children with SCA with a median age of 10.8 years (interquartile range 7.2) were followed for a median of 4.9 years (interquartile range 1.8). Overnight polysomnography evaluations at baseline health exam were measured and adjudicated centrally. Multivariable models created in two steps were included. First, all plausible covariates were included in a screening model. Subsequently, covariates meeting level of statistical significance of P < .20 were included in the final model. Contrary to our hypothesis, higher (but not lower) mean nocturnal SpO 2 was associated with higher rates of pain episodes (Incidence rate ratio (IRR) 1.10, 95% CI [1.03-1.18], P 5 .004). Higher log OAHI did not pass screening criteria. Higher log ODI was not significantly associated with higher rates of pain episodes (IRR 0.93, 95% CI [0.82-1.06], P 5 .28). Neither low nocturnal SpO2, higher OAHI, nor higher ODI were associated with clinically relevant increased incidence rates of acute severe pain episodes.
| I N TR ODU C TI ON
Sickle cell anemia (SCA) is the most common inherited blood disorder in the United States, and the burden is continuing to increase worldwide. 1 The two most common complications of SCA requiring hospitalization are acute vaso-occlusive pain (referred to as pain) and acute chest syndrome (ACS) episodes. One potential risk factor for sickle cell disease (SCD) related morbidity is hemoglobin oxygen desaturation, which leads to hemoglobin polymerization, sickling of erythrocytes, and increased red blood cell adherence to the endothelium, ultimately resulting in vaso-occlusion and tissue hypoxia. 2, 3 Previous studies have investigated the relationship between hemoglobin oxygen saturation, as measured by pulse oximetry (SpO 2 ), and SCA-related morbidity with conflicting results. In a prospective cohort of 130 children with SCA, there was no association between lower mean daytime SpO 2 obtained at baseline health exam and incidence rates of pain or ACS. 4 Similar findings were seen in a retrospective cohort of 183 children with SCA from the Dallas Newborn Cohort for incidence rates of ACS episodes. 5 In a third study, a prospective single-center cohort of 39 consecutive children with homozygous SS or S/b 0 thalassemia, neither mean daytime nor mean nocturnal SpO 2 was associated with increased incidence rates of pain or ACS episodes. 6 The prior three studies measuring mean SpO 2 levels (three daytime studies and one nighttime study) have not demonstrated any association between lower mean SpO 2 and increased incidence of pain or ACS in children with SCA. In contrast, only one study has demonstrated a positive association. A single site prospective study by Hargrave et al. demonstrated that low mean nocturnal SpO 2 , based on overnight pulse oximetry measured either at home or in-patient, was associated with an increased number of hospital days for pain episodes. 7 Conflicting results describing the relationship between low mean nocturnal SpO 2 measurements and SCA morbidity (pain and ACS episodes) has resulted in ambiguity as to whether children with low mean nocturnal SpO 2 should be prescribed supplemental oxygen at night to prevent SCA related morbidity.
The National Heart Lung and Blood Institute funded our multidisciplinary research team of pediatric hematologists, pulmonologists, and sleep experts to address whether mean nocturnal SpO 2 predicted future pain episodes requiring hospitalization. We created a multicenter prospective cohort of unselected children with SCA that received a full 12-channel polysomnography (PSG). In this cohort, we tested the primary hypothesis that low mean nocturnal SpO 2 is associated with increased incidence rates of pain episodes in children with SCA. We also tested the hypothesis that obstructive sleep apnea syndrome (OSAS), as defined by high obstructive apnea-hypopnea index (OAHI) or by high oxygen desaturation index (ODI), is associated with an increased incidence of pain episodes in children with SCA. Finally, we explored whether there is any relationship between mean nocturnal SpO 2 , OAHI, and ODI and increased incidence of ACS episodes in children with SCA.
| M E TH ODS
A prospective cohort study of children and adolescents from the Sleep for respiratory disease and prospectively observed for at least 3 years.
Children were not eligible for participation in the study if they received long-term blood transfusion therapy due to the known impact of transfusion therapy on pain episodes. 8 Participants were also not eligible if they received long-term continuous positive airway pressure support, had chronic lung disease other than asthma, smoked cigarettes, or were known to be human immune deficiency virus (HIV)-positive due to the known association between HIV-positivity and chronic lung disease in children and adolescents. 9 If patients began regular blood transfusion therapy during the study period, they were retained in the cohort and a separate analysis was performed including these participants. Parents provided written informed consent for all participants and patients provided assent when appropriate. Laboratory testing, daytime SpO 2 , and polysomnography were performed at study entry when patients were at baseline health. Study visits were in coordination with routine clinical care and participants were followed every three to six months. 
| Polysomnography
At each study site, SAC study-certified technicians performed overnight full 12-channel, in-laboratory research PSG including the following: monitoring of electroencephalography (EEG), eye movements (electro-oculogram, (EOG)), chin and limb electromyogram (EMG), thoracic and abdominal respiratory effort, airflow (thermistor and nasal pressure transducer), snore sensor, electrocardiography (ECG), and continuous measurements of nocturnal SpO 2 (using Masimo SET (v2), Irvine, CA). All data collection utilized standardized protocols according to the American Academy of Sleep Medicine guidelines for data acquisition and pediatric scoring. 13 All PSGs were read centrally at Vanderbilt University School of Medicine.
| Statistical analysis
Negative binomial regression was used to test the association between nocturnal SpO 2 and the incidence rates of pain and ACS episodes.
Covariates in the primary models for pain and ACS episodes included:
age at the time of the sleep study, gender, hemoglobin, white blood cell count (WBC), OAHI, and mean nocturnal SpO 2 . The log value of OAHI and ODI was used for a continuous measure because the distributions were positively skewed. Multivariable models were constructed in two steps. First, all covariates were included in a screening model.
Subsequently, those covariates meeting a significance criterion of P < .20 were included in the final model for pain or ACS episodes. The variance inflation factor (VIF) was used to assess multicollinearity using a threshold of 3.0. The highest VIF value was 1.6, indicating that collinearity is not a concern in these data. All tests for significance were two-tailed. P-values of < .05 were considered significant in the final models. Analyses were conducted using IBM SPSS Statistics (Version 23, Armonk, New York, IBM).
| R E SU LTS

| Recruitment and baseline characteristics
Of the 252 participants with SCA who underwent PSG, 243 had complete data that were able to be scored according to the American Academy of Sleep Medicine guidelines. 13 Of these, 223 participants had values for pain and ACS after PSG; missing data were due to lack of follow-up. Among the 223 participants, 18 participants were on hydroxyurea therapy at the time of PSG and one had a missing hydroxyurea status. These 19 participants were excluded from the primary analyses due to the known association between hydroxyurea and increased baseline SpO 2 measurements (hydroxyurea results in an increase in the percentage of fetal hemoglobin [HbF] and shifting of the oxygen dissociation curve to the left). 14 After PSG was completed, 59 patients were started on hydroxyurea therapy, 6 were started on chronic blood transfusion therapy, and 1 participant was started on both therapies. These individuals were not included in the primary analysis ( Figure 1 ). We did include the participants that started hydroxyurea, regular blood transfusion therapy or both after polysomnography in a secondary analysis, and there was no appreciable difference in the results (see Supporting Information).
The final sample included 140 participants with a median age of 10.8 years (IQR 7.2). Participants were followed for a median of 4.9 years (IQR 1.8) after PSG, 
| D I SCUSSION
When a child with SCA has a low nocturnal SpO 2 and a history of increased acute pain episodes, clinicians are without clear evidence that the use of supplemental oxygen will attenuate the incidence of future acute pain episodes. We conducted a prospective cohort study of children with SCA receiving rigorously performed sleep studies to determine if mean nocturnal SpO 2 was associated with either future pain or ACS episodes. Our results did not provide any evidence that low mean nocturnal SpO 2 , high OAHI, or high ODI measurements were associated with increased incidence rates of pain or ACS episodes.
Despite having results contrary to our hypothesis, we believe our results are credible for the following reasons: (1) consistency of our findings with the two other prospective cohort studies demonstrating that mean daytime SpO2 was not associated with increased incidence rates of pain 4, 6 ; (2) 
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Undoubtedly after completion of any study that did not confirm the primary hypothesis (and found a reverse association), there is some concern about spurious results and power of the study to test the hypothesis. However, these concerns are reduced for our study because we did find statistically significant results, with a moderatesized coefficient, albeit in the opposite direction of the hypothesis (higher, not lower, SpO 2 measurements are associated with increased acute pain episodes). Second, in our cohort, similar to previous studies that did not find a relationship between low mean daytime SpO 2 and SCA related morbidity. [4] [5] [6] In our study, for the primary hypothesis, the 95% confidence interval is narrow, describing the relationship between which distinguish their study design from our study, include, but are not limited to: a single-center study which typically overestimates the effect size; 18 the use of a pulse oximeter reading without the full benefit of polysomnography evaluation, which is considered the gold standard for assessment of nocturnal desaturations; and the primary analysis which did not correct for multicollinearity. Additionally, in our study we determined mean nocturnal SpO 2 measurement as part of an overnight PSG study using a Masimo pulse oximeter. An inherent challenge in using pulse oximetry measurements is the ability to differentiate true desaturation from motion artifact. A study of 20 pulse oximetry machines demonstrated that the Masimo SET R machine used in our cohort exhibited the best overall performance, with a sensitivity and specificity of 98% and 93%, respectively. 19 In contrast, the Hargrave et al. analysis used Ohmeda Biox 3700, a machine with relatively poor test characteristics. 20 Another major difference between our study and Hargrave et al. was the primary outcome measure. Our primary measure for severity was discrete events of acute vaso-occlusive pain, the standard strategy for assessment of pain in SCA therapeutic trials; 21, 22 in comparison, Hargrave et al. elected to use the number of acute pain days in the hospital, an outcome that may be more variable based on family dynamics and physician preference. Table 3 summarizes the similarities and differences between the current study and Hargraves et al.
Despite the observation that an increase in OAHI was not associated with an increase in the incidence of ACS in our study, the direction of the association (higher OAHI is associated with higher incidence rate of ACS) is in agreement with our understanding of the pathophysiology of SCA. When including the cohort receiving disease modifying therapy, our results are just barely above the level of statistical significance, and do not exclude the possibility that higher OAHI correlates with higher risk for ACS. In this cohort, the median OAHI of 0.6 is in the range of normal, 23 suggesting our population is similar to the general population of children without SCA. Thus, in a child with SCA that has recurrent ACS episodes and evidence of severe OSAS, specific interventions may be considered given the benefits in the general pediatric population. 24 However, a prospective cohort study would need to validate the potential benefits and risks of this intervention for decreasing SCA related morbidities or other morbidities.
Our study had several limitations. In our study, hydroxyurea was not associated with a decrease in the rates of pain and ACS during the study period, thus we elected to exclude participants on hydroxyurea and started on chronic blood transfusion therapy after initial PSG.
However, our results are generalizable to most children with SCA because despite a clear benefit of hydroxyurea therapy, almost a third 
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